DeWitt Katie, Bjornstad Petter, Bergmann Kelly R
Pediatric Emergency Medicine, Children's Minnesota, Minneapolis, USA.
Medicine, University of Washington (UW) Medicine Diabetes Institute, Seattle, USA.
Cureus. 2024 Jul 1;16(7):e63588. doi: 10.7759/cureus.63588. eCollection 2024 Jul.
The cost associated with type 1 diabetes care is considerable and the rising price of insulin has further amplified this financial burden. To curb insulin costs, numerous policies have been enacted in the past five years, both by pharmaceutical companies and their intermediaries, as well as federal and state legislatures. The most notable example is implementation of insulin cost-sharing cap laws, which place limits on out-of-pocket expenses for insulin, and in some cases, diabetes technology. Although insulin cost-sharing cap laws have the potential to mitigate the financial burden associated with routine diabetes care, these policies have largely benefitted adults living with type 1 diabetes, while children, especially those from racial and ethnic underrepresented groups, appear to have derived limited advantage. We describe the current state of insulin cost-sharing cap laws and utilization among children and adolescents with type 1 diabetes, with a focus on the limitations of current insulin laws, the importance of measuring health outcomes for children who utilize such programs, and the impact on health equity. We provide a call to action for policymakers and provide recommendations for future research in this area.
1型糖尿病护理的相关成本相当高昂,胰岛素价格的上涨进一步加剧了这一经济负担。为了控制胰岛素成本,在过去五年里,制药公司及其中间商以及联邦和州立法机构都制定了许多政策。最显著的例子是实施胰岛素费用分摊上限法律,该法律对胰岛素的自付费用进行限制,在某些情况下,还包括糖尿病治疗技术的费用。尽管胰岛素费用分摊上限法律有可能减轻与常规糖尿病护理相关的经济负担,但这些政策在很大程度上使成年1型糖尿病患者受益,而儿童,尤其是来自种族和族裔代表性不足群体的儿童,似乎受益有限。我们描述了胰岛素费用分摊上限法律以及1型糖尿病儿童和青少年的使用现状,重点关注当前胰岛素法律的局限性、衡量使用此类项目儿童健康结果的重要性以及对健康公平性的影响。我们呼吁政策制定者采取行动,并为该领域未来的研究提供建议。